Transitions from small cell (SCLC) to non-small cell lung cancer (NSCLC) cells have been documented both in vitro and in vivo and are thought to be an important step during tumor progression of human small cell lung cancer towards a treatment-resistant tumor state. We have screened NSCLC and SCLC cell lines for dierences in the composition of nuclear transcription factors using consensus oligonucleotide sequences (SRE, Ets, TRE, CRE, B-motif, GAS, E-box). We found NSCLC cells to exhibit signi®cantly higher AP-1 binding activity than SCLC cells consistent with the increased expression of CD44, an AP-1 target gene. To gain more insight into the molecular mechanisms underlying these dierences, we analysed SCLC cell lines (NCI-N592 and NCI-H69) which were phenotypically transformed into NSCLC-type cells by transfection with activated H-ras and c-myc oncogenes. In these cells, ras-induced transition is accompanied by a strong induction of AP-1-binding activity along with increased expression of CD44 mRNA and protein. When analysing the composition of the AP-1 complex in more detail and comparing ras-induced versus phorbol ester-induced changes, we found Fra-1 to be the major component induced in ras-transfected but not in phorbol-ester treated or non-treated parental SCLC cells. This ®nding is paralleled by the observation that among the various members of the Fos and Jun family analysed (c-Fos, FosB, Fra-1, Fra-2, c-Jun, JunD, JunB) fra-1 is the only gene to be exclusively expressed in NSCLC cells but not in cells of SCLC origin. Our data, thus, point to a histiotype-related mechanism of recruitment among AP-1 proteins which may have bearings on the fate of lung cancer development.
Introduction
Lung cancer is the leading cause of tumor-related death in both men and women. Tumors arising in the lung form a heterogenous group by histology which can be classi®ed into four major subgroups: small cell carcinoma (SCLC), accounting for 25% of human lung tumors, squamous cell carcinoma, large cell carcinoma and adenocarcinoma, collectively termed non-small cell lung carcinoma (NSCLC). Due to their dierent phenotypic properties, the various types of lung cancer are supposed to originate from dierent cell types of the bronchial epithelium and alveoli. In clinical practise, however, lung cancer frequently exhibits more than one histologic pattern (Kalemkerian and Mabry, 1993; Mabry et al., 1988 Mabry et al., , 1991 Roggli et al., 1985) . Thus, mixtures of cells with SCLC and NSCLC histologies appear in SCLC tumors and, moreover, both SCLC and NSCLC phenotypic markers have been detected simultanously in individual cells. These observations have led to the hypothesis that in vivo transitions from an SCLC to an NSCLC phenotype might occur. Further evidence in favour of this hypothesis came from in vitro experiments in which overexpression of activated Hras and c-myc oncogenes in SCLC cell lines resulted in the loss of SCLC-speci®c markers and gain of phenotypic characteristics resembling those of NSCLC cells (Mabry et al., 1988 BuÈ rger et al., 1994 . Such cell type transitions may be crucial for the progression of each lung cancer type and its resistance to current modes of therapy.
Although the molecular events underlying these cell type transitions have not yet been elucidated, it is likely that distinct transcription factors are involved in this process. This is exempli®ed by the aforementioned in vitro observation that the combined action of H-ras and c-Myc is sucient to promote`transdierentiation' into a dierent phenotype. c-Myc itself is a member of a larger family of transcription factors binding to the E-box element (for review see Amati and Land, 1994; Bernards, 1995) while H-ras as a signal transduction molecule transmits its activity via the Raf-MAP kinase pathway (reviewed in Karin and Hunter, 1995; Marshall, 1995) and modulates the activity of distinct nuclear transcription factors, such as the activity of AP-1, Ets/TCF and NF-kB proteins. Alteration of AP-1 activity has been particularly associated with increased Ras activity and therefore has been extensively characterized in the past (for review see Angel et al., 1987; Hill and Treisman, 1995; Marshall, 1995) . AP-1 consists of proteins of the Jun and Fos families which associate as homo-(Jun/Jun) or heterodimers (Fos/Jun; reviewed in Angel and Karin, 1991; Cohen and Curran, 1990) . To date, three Jun proteins (c-Jun, JunB and JunD) and four Fos family members (c-Fos, FosB, Fra-1 and Fra-2) have been identi®ed as components of the AP-1 factor (Bohmann et al., 1987; Cohen and Curran, 1988; Hirai et al., 1989; Nakabeppu et al., 1988; Nishina et al., 1990; Ryder et al., 1989; Zerial et al., 1989) . Fos/Jun heteroor Jun/Jun homodimers recognize a cis-acting element, the phorbol 12-myristate 13-acetate (TPA)-responsive element (TRE: TGACTCA), which is found in a number of cellular promoters such as the genes coding for interstitial collagenase, transin, typeIV collagenase, procathepsin L or CD44 (Angel et al., 1987; Hofmann et al., 1993; Kerr et al., 1988; Sato and Seiki, 1993; Troen et al., 1991) .
While AP-1 activity is generally associated with proliferation (Angel and Karin, 1991; Kovary and Bravo, 1992) it is also an important signaling component in various dierentiation processes involving growth arrest (Dixit et al., 1993; Melamed et al., 1993) or apoptosis (Estus et al., 1994; Goldstone and Lavin, 1994; Smeyne et al., 1993) . Most of these eects have been reported in cell systems of diverge tissue origin and thus, the function of AP-1 seems to be dependent not only on the pathway of signal --------+  +  +  +  +  +  +  +   H69 H82 H841 H146 32M1 103H H1573 H2077 PMA fp -SCLC NSCLC c Figure 1 AP-1 DNA binding activity in NSCLC (a) and SCLC cell lines (b). Whole cell extracts (10 mg) were prepared from NHBE cells and NSCLC and SCLC cell lines as described under Materials and methods either in the presence (+) or absence (7) of 5610 78 M PMA added for 24 h (indicated above the lanes). Aliquots were incubated with 32 P-labeled, double-stranded consensus AP-1 DNA binding sequence. The bound complexes were resolved on a 4% polyacrylamide gel (fp=free probe). (c) Same experimental approach using a double-stranded consensus sequence for SP-1 as control for equal quality of extracts (shown only for eight cell lines) transduction itself but also on the context of cellular dierentiation.
In this study, we have screened a number of transcription factors with respect to their binding potential in lung cancer cell lines of dierent histological origin. Among these, we found AP-1 to be a protein complex which is abundantly present in NSCLC but not in SCLC cells. Using H-ras/c-myc transfected SCLC cells, we can further show that upon transition from SCLC-to NSCLC phenotype these cells also gain strong AP-1 DNA binding capacity along with elevated AP-1 dependent gene expression. The strong TRE-binding activity in these NSCLC-like cells is largely achieved by the recruitment of Fra-1 into the complex the expression of which also is a hallmark of NSCLC cells. This ®nding, thus, may point to a histiotype-related mechanism of regulation among members of the AP-1 family in lung cancer cells.
Results
Comparison of sequence-speci®c DNA-binding activities in NSCLC and SCLC cell lines A collection of 12 NSCLC and 11 SCLC cell lines was examined in electrophoretic mobility shift assays (EMSA) for the presence of proteins binding to dierent synthetic consensus sequences. The latter either corresponded to consensus sites for nuclear factors involved in the Ras-MAP kinase signaling pathway such as the TRE (TPA-responsive element, also referred to as AP-1 binding site), Ets element (binding site of TCF), the SRE (serum-responsive element), E-box (binding site of Myc/Max proteins), kB site (binding site of NF-kB) or to transcription factors involved in other signal transduction pathways such as the CRE (cAMP-responsive element) and GAS element (binding site of STAT factors). While the binding activities for most of these target sequences did not vary signi®cantly between NSCLC and SCLC cells (data not shown), we observed a marked dierence in the level of AP-1 DNA binding activity being abundant in the majority of the NSCLC cell lines but barely detectable in most of the SCLC cell lines analysed (Figure 1 ). This ®nding prompted us to further investigate whether the level of AP-1 complex found would also correlate with functional transcriptional activity in these cells. As an example, we monitored the expression of the CD44 gene by RT ± PCR since this gene is expressed in cells of epithelial origin and known to harbor an AP-1 consensus element within the proximal promoter region (Homann et al., 1993) . As shown in Figure 2 , the majority of NSCLC cells but not of SCLC cells revealed clearly detectable CD44 mRNA levels which largely corresponded with the relative amount of TRE-binding activity in this cell-type.
TRE-binding activity and AP-1 dependent gene transcription in SCLC cells phenotypically transformed to NSCLC
To gain more insight into the molecular mechanisms underlying these histiotype-borne dierences, we took advantage of an established in vitro system, in which SCLC cell lines (cell lines NCI-N592 and NCI-H69) are induced to adopt properties of an NSCLC phenotype by transfection and thus overexpression of c-myc and activated H-ras oncogenes (BuÈ rger et al., 1994) . The transfected cells are characterized by distinct NSCLC-like properties such as adherent growth, gain of expression of NSCLC-speci®c genes and loss of expression of SCLC-speci®c genes (BuÈ rger et al., 1994) . Comparing extracts from transfected and non-transfected cells in analogous EMSA experiments, we found that the TRE-binding capacity is highly upregulated upon transition from the SCLC to the Hras/c-myc induced NSCLC phenotype. (Figure 3a) . Competition experiments using a mutant TREoligonucleotide indicated that the AP-1 DNA binding activity present in the transfected cells was speci®c for this sequence (Figure 3b ). To make sure that the dierences observed for the parental and transfected cells with respect to their TRE-binding activities were not due to a reduced quality of the extracts, we performed EMSA using a consensus oligonucleotide for the transcription factor SP-1 instead of AP-1 (Figure 3c ). Next, we also monitored the extent of CD44 mRNA induction as previously done for NSCLC and SCLC lung cancer cell lines. As anticipated, all three H-ras/c-myc transfected subclones reveal a markedly increased expression of CD44, contrary to a non-adherent clone transfected with the empty expression vector (N592C, Figure 4a ). ]dCTP was added to the PCR reaction to allow the sensitive detection of ampli®ed DNA fragments using only a limited number of PCR cycles. The reaction products were electrophoresed on 6% polyacrylamide gels and visualized by autoradiography. In case of CD44 a 166 bp fragment (CD44 non-spliced transmembrane region) is ampli®ed (25 PCR cycles). GAPDH transcription served as control for equal cDNA content (300 bp fragment, 20 PCR cycles) Interestingly, the extent of gene induction correlates with the amount of nuclear factors binding to the TRE-consensus element (cf. Figures 3 and 4 ; H69.54H69.444H69; N592.544N592). Finally, we examined the level of CD44 glycoprotein present at the cell surface in order to test whether the dierence in AP-1 content would lead to persistent altered protein expression. This time we analysed sections of xenograft tumors derived from both parental and transfected N592 and H69 cell lines by immunohistochemistry. As shown in Figure 4c , tumor tissue derived from transfected NSCLC-like subclones exhibits a much stronger CD44-related membrane staining than tissue of the non-transfected counterparts, which contains only marginally detectable CD44 immunoreactivity. Thus, in these cells, AP-1 content, transcription of AP-1 target genes and subsequent protein expression seemed to be closely linked. Characterization of the AP-1 complex induced in c-myc and Ha-ras transfected SCLC cells
Having established a correlation between NSCLC-type and augmented AP-1 activity, we next examined the composition of the AP-1 complex more precisely by performing AP-1 DNA binding assays in the presence of inhibiting or supershifting antibodies directed against Jun and Fos family proteins, i.e. against c-Jun, JunB, JunD, c-Fos, FosB, Fra-1 and Fra-2. These antisera had been raised against fusion proteins linked to bgalactosidase or against peptide epitopes of dierent Fos and Jun proteins and had been previously shown to speci®cally interfere with the formation of Fos/Jun complexes in electrophoretic mobility shift assays (Adamkiewicz et al., 1990 (Adamkiewicz et al., , 1993 . We ®rst incubated extracts of H-ras/c-myc transfected SCLC cells with these dierent antisera. Figure 5a shows that several antisera aected the binding potential signi®cantly. As an example, antibody a Pan AP-1, directed against the highly conserved DNA-binding domain of AP-1 proteins, almost completely inhibited the formation complexes in N592.5 as well as in H69.5 cells (data only shown for clone N592.5). Two antisera directed against c-Fos, a c-Fos (455) and a c-Fos (P3), did not interfere with the formation of speci®c protein-DNA complexes while with a Fos-B antibody a weak supershifting activity could be observed. Three antisera directed against c-Jun, on the other hand, largely interferred with DNA binding. Antisera K30 (rabbit polyclonal against entire c-Jun), jp 5/6 (rabbit polyclonal against cJun DNA binding region) strongly inhibited complex formation while another antiserum to c-Jun (Santa Cruz Biotechnology Inc.) supershifted part of the TREprotein complex. Similar eects were seen with antibodies directed against JunD and Fra-1. Antisera directed against JunB and Fra-2 had no detectable eect. From these data we can conclude that the AP-1 DNA binding complex in extracts from transfected NSCLC-like cells is mainly composed of c-Jun, JunD and Fra-1 (data summarized in Table 1 ). In order to be able to distinguish ras-induced alterations of AP-1 components in these cells from the`normal' AP-1 content, we next analysed the AP-1 complex in the parental H69 and N596 cell lines using the same approach. As in these cells the basal level of TRE-binding was very low, we used extracts from cells which had been stimulated with PMA and therefore exhibited an induced TRE-binding activity. A comparable level of total AP-1 protein could be achieved only in N592 cells following 6 h of PMA treatment ( Figure  5b ). Under these conditions, we found c-Fos, FosB and c-Jun to be the major components of the AP-1 complex (Figure 5a , lower panel). JunD and Fra-1 could not be detected in the AP-1 DNA binding complex. Finally, in order to be able to directly compare the composition of the AP-1 complex in parental and H-ras/c-myc transfected subclones, we also analysed extracts of PMA-stimulated N592.5, H69.4, and H69.5 cells (results for clone N592.5 shown in Figure 5a , middle panel). As in case of the non-stimulated transfected cells, the major components of the AP-1 complex were c-Jun, JunD and Fra-1 while an induction of c-Fos and FosB activity could not be observed. This ®nding therefore indicates that transfection by H-ras and cmyc resulted in a persistent change in the composition of AP-1 proteins along with a decreased sensitivity to PMA. A summary of these ®ndings is given in Table 1 . Although one has to take into account the dierent anities of the antisera used it becomes evident from these data that stimulation by PMA and H-ras/c-myc overexpression have markedly dierent eects with regard to the recruitment of speci®c AP-1 proteins.
To further test whether the change in AP-1 activity and composition in transfected SCLC cells was for 6 h and 24 h, respectively. Seen is the induction of AP-1 binding activity in cell line N592 (maximum after 6 h) and transfected derivatives of both cell lines dierences in the level of expression are observed for cfos and junD and signi®cant dierences with respect to fosB and fra-1 mRNA. Variations in junD, c-fos and fosB mRNA levels, however, do not coincide completely with the H-ras/c-myc-induced phenotype since e.g. c-fos is upregulated also in cells transfected with a mock plasmid (N592C), fosB is downregulated in the same cells, and junD expression not induced in H69.4 cells. The most obvious, speci®c change is seen with respect to fra-1 mRNA expression. mRNA coding for Fra-1 is hardly detectable in the parental cell lines N592 and H69 and the control cells N592C but signi®cantly induced in H-ras/c-myc-transfected subclones N592.5, H69.4 and H69.5. This result is consistent with the previous ®nding that the AP-1 complex in these three subclones but not in the parental cells contains functionally active Fra-1. Thus, fra-1 expression seemed to be the most consistent parameter diering between the two states of cells examined.
Fra-1 is dierentially expressed in NSCLC and SCLC cell lines
Finally, to see whether components of AP-1 might also be dierentially regulated in other lung cancer cell lines, we monitored the level of expression of all AP-1 family members in the NSCLC and SCLC cell lines which had been analysed for their TRE-binding capacity before. As method of choice we performed RT ± PCR analysis in order to look at dierences in the activity of the respective genes. The result of this survey is given in Figure 7 . While no marked dierences were observed for the expression of cfos, fra-2, c-jun and junB, we found a generally elevated number of transcripts coding for junD in most of the NSCLC cells. We also noted varying expression with respect to fosB mRNA ranging from no detectable expression to relative abundance in both SCLC and NSCLC cell lines. Again, the most obvious dierence between NSCLC and SCLC cells was seen with respect to fra-1 expression. mRNA coding for Fra-1 was practicably not detectable in all SCLC lines analysed. On the contrary, all NSCLC cell lines with one exception (NCI-H2077) do express signi®cant amounts of this gene. These ®ndings indicate that elevated fra-1 expression is not only found in phenotypically converted SCLC cells as a consequrence of H-ras and c-myc overexpression, but is more generally a distinct marker of NSCLC character. Values are based on autoradiographic data shown in Figure 5 . Symbols denote the degree of antibody-mediated binding inhibition as determined by densitometry: (7) . Due to the location of the primers used two fra-1 fragments representing naturally occurring transcripts have been detected . Parental N592 and H69 SCLC cells do not exhibit detectable fra-1 transcription
Discussion
In this study we have analysed molecular events underlying the transition from SCLC to NSCLC phenotype of two lung cancer cell lines expressing Hras and c-myc transfected oncogenes. As a result, we found that these cells dier from their corresponding parental cells by an increased AP-1 DNA binding activity (see under Results) contrary to the binding activities of other transcription factors analysed (data not shown). Moreover, we can show that in SCLC cells expressing these oncogenes the composition of the AP-1 complex diers markedly from complexes induced by activators of protein kinase C such as phorbol esters. While the former complex contains signi®cant amounts of Fra-1 protein the phorbol ester induced complex does not. We can further provide evidence that this ®nding is not restricted to H-ras/c-myc transfected cell clones but seems to be a general characteristic for nearly all NSCLC cell lines analysed. Contrary to SCLC cells and in line with the aforementioned transfected SCLC clones, most cell lines of NSCLC origin exhibit (i) a detectable amount of constitutive AP-1 binding activity which is readily inducible by phorbol esters, (ii) constitutive expression of fra-1 and (iii) expression of CD44, a target gene of AP-1 activity.
Transitions between small cell and non-small cell carcinoma have been observed both in vivo and in vitro (Barr et al., 1996; BuÈ rger et al., 1994; Falco et al., 1990; Kalemkerian and Mabry, 1993; Mabry et al., 1988 Mabry et al., , 1991 . A model system to study the molecular events underlying these transitions has been recently established by transfecting an activated Ha-ras gene into myc-expressing SCLC cells which causes transition to a NSCLC phenotype resembling large-cell, undifferentiated cancer (Barr et al., , 1996 BuÈ rger et al., 1994; Falco et al., 1990; Mabry et al., 1988) . Since overexpression of H-ras in SCLC cells alone does not lead to full phenotypic conversion, it has been necessary in the past to either select SCLC cells which overexpress an endogenously ampli®ed c-myc or N-myc gene, or to co-express a transfected human c-myc gene, thus permitting progression of SCLC into NSCLC (Barr et al., 1996; BuÈ rger et al., 1994; Falco et al., 1990) . This raises the question as to which of the two oncogenes expressed in the transfected SCLC subclones contributes more to the altered AP-1 binding activity. Although this aspect has not been clari®ed in the present study, several lines of evidence suggest that this eect is more a consequence of Ras function rather than that of Myc. First of all, the role of Ras in signal transduction pathways that lead to the activation of NHBE  32M1  U1752  97TM1  103H  U1810  H23  H125  H820  H1573  H2009  H2126 H82  H841  H146  H187  86M1  DMS79  H526  H1092  H510  SW210  24H SCLC AP-1 has been fundamentally established in numerous reports (reviewed in Karin and Hunter, 1995; Marshall, 1995) . Members of the myc family, on the other hand, are frequently overexpressed in SCLC including several SCLC lines analysed in this study (c-myc, cell line SCLC-24H, NCI-H82; N-myc, cell lines NCI-N592, SCLC-86M1; L-myc, cell lines SCLC-24H, SCLC-86M1, NCI-H69, and NCI-H82; see (BuÈ rger et al., 1994) . In this collection of SCLC cell lines analysed, however, we could not observe any correlation between myc overexpression and AP-1 content or CD44 gene expression. Moreover, our analysis of E-box binding activity in SCLC cell lines including N592 and H69 and oncogene transfected derivatives revealed a relatively uniform pattern (data not shown). Thus, activated Ras may be the likely component to achieve altered TRE-binding and CD44 target gene activation in the cell lines examined although a permissive eect of c-myc cannot be excluded. The upregulation of TRE-binding activity in H-ras/ c-myc transfected SCLC cells implies several possibilities of AP-1 complexes to form. Due to the relative increase in Fra-1, cJun and JunD we expect either Fra-1/c-Jun or Fra-1/JunD heterodimers to form or c-Jun or JunD homodimers. Since both homodimers possess much weaker DNA-binding activities than the heterodimers (Ryseck and Bravo, 1991) , it is likely that heterodimeric proteins make up the bulk of AP-1 binding activity. It is noteworthy that these two heterodimers have dierent transcriptional regulatory function, the Fra-1/c-Jun heterodimer being an extremely poor, the Fra-1/JunD a very ecient transactivator of AP-1 regulated gene expression (Suzuki et al., 1991) . The Fra-1/JunD heterodimer has been shown to play an important regulatory role in the AP-1 dependent expression of the human urokinase-type plasminogen activator receptor gene in colon cancer cells (Lengyel et al., 1996) and of the human involucrin gene in keratinocytes (Welter et al., 1995) . Interestingly, neither Fra-1 nor JunD were found in AP-1 complexes of PMA-induced parental SCLC cells. Thus we can conclude that the high TREbinding activity we observe in ras/myc transfected SCLC cells phenotypically transformed to NSCLC cells is achieved by speci®c recruitment of distinct AP-1 proteins to a functional AP-1 complex.
The most interesting result was obtained with respect to the dierential fra-1 expression in NSCLC and SCLC cell lines pointing to a dierential histiotype-related mechanism of regulation. Fra-1 has been identi®ed in heart and skeletal muscle (Hannan et al., 1993; Park et al., 1992) , brain (Persico et al., 1993) , leukocytes (Boise et al., 1993) , ®broblasts (Braselmann et al., 1993) , adipocytes (Stephens et al., 1993) , the vascular system (Miano et al., 1993) , in skeletal tissues , in keratinocytes (Welter et al., 1995) and in colon cancer (Lengyel et al., 1996) . Based on our data, we now describe a possible tissue-speci®c function of Fra-1 in human lung cancer cells. Evidence for such a role comes not only from the dierential gene expression in lung cancer cell lines, but also from the altered transcriptional status detected in the phenotypically transformed lung cancer cells. Thus, Fra-1 is highly expressed in H-ras/c-myc transfected SCLC but hardly detectable in the parental SCLC cells. fra-1 was originally isolated as an immediate-early gene which encodes a Fos-related antigen crossreacting with c-Fos antibodies (Cohen and Curran, 1988) . Serum growth factors stimulate transcription from the promoter of this gene in a delayed-early type of response contrary to that of c-fos and fosB induction which both are of the immediate-early type (Cohen and Curran, 1988; Kovary and Bravo, 1992) . Recently, it has been shown in NIH3T3 cells that fra-1 is absent from cycling cells but accumulates in cells expressing oncogenic Ras protein Mechta et al., 1997) . In these cells, c-Jun and Fra-1 are the major components of AP-1 activity and, as shown by co-transfection experiments, probably the mediators of Ras-transformation. This ®nding is in line with our own data based on the analysis of SCLC cells. Similarly, we ®nd Ras to have the same profound eects on the composition of the AP-1 complex as in NIH3T3 cells leading to the accumulation of Fra-1 and c-Jun. Our results dier only with respect to JunD which is moderately upregulated in the three H-ras/cmyc transfected SCLC clones analysed but is not aected in Ras-transformed NIH3T3 cells (Mechta et al., 1997; Pfarr et al., 1994) , a function which may not account for SCLC cells. The second important implication according to Lallemand et al. is that fra-1 is absent from cycling cells. Although this observation does not imply that Fra-1 has no function in cycling NIH3T3 cells (see Kovary and Bravo, 1992) it would explain our own observation that SCLC cell lines which show no fra-1 expression have cell doubling times which are comparable to the majority of NSCLC lines which do express this gene. These data, therefore, make it more likely that Fra-1 in lung cancer cells may not be linked to cell cycle activity but may rather constitute a marker in the cell type transition pathway coinciding with the expression of NSCLC markers.
One consequence which most likely results from the induction of TRE-binding activity in phenotypically converted SCLC cells is the elevated expression of CD44. This gene has been shown to be AP-1 responsive due to a TRE in its promoter (Hofmann et al., 1993) . In addition CD44 expression is upregulated in cells transformed by either v-src or activated H-ras (Hofmann et al., 1993; Jamal et al., 1994) , which suggestes that CD44 expression is normally regulated by signaling pathways in which these oncogenes participate. The product of the CD44 gene itself is a cell surface transmembrane proteoglycan and appears to mediate a diverse range of functions in dierent cell types (Haynes et al., 1991; Sherman et al., 1994) . CD44 has been shown to function in both cellcell and cell-ECM interactions through binding to hyaluronan, ®bronectin, collagen and osteopontin (Aruo et al., 1990; Jalkanen and Jalkanen, 1992; St. John et al., 1990; Weber et al., 1996) . Our ®nding that CD44 is preferentially expressed in NSCLC cell lines also is in line with previous reports which show that CD44 is preferentially expressed in NSCLC-type tumors but not in SCLC (Givehchian et al., 1996; Penno et al., 1994; Wimmel et al., 1997) and as such can be viewed as an NSCLC-speci®c marker. In the light of these data also the NSCLC character of H-ras/ c-myc transfected SCLC clones is supported. Whether the gain of additional CD44-related adhesion functions might be responsible for the adherent growth of NSCLC in contrast to SCLC cells, however, remains to be shown.
In conclusion, our data suggest, that SCLC cells upon H-ras/c-myc-induced morphological conversion to NSCLC cell phenotype reveal enhanced AP-1 activity, upregulation of fra-1 expression, recruitment of Fra-1 protein to the TRE-binding complex, and activation of AP-1 dependent gene expression, eects, which are also a hallmark of nearly all NSCLC lines analysed. These results, therefore, may point to a general involvement of AP-1 proteins, namely that of Fra-1, in the transition from SCLC to NSCLC phenotype and in the maintainance of dierentiation speci®c functions in NSCLC cells.
Materials and methods

Cell lines
The human lung carcinoma cell lines used in this study include the NSCLC lines EPLC-32M1, U1752 (squamous cell carcinomas), LCLC-103H, U1810, LCLC-97TM1 (large cell carcinomas), NCI-H23, -H125, -H820, -H1573, -H2009, -H2077, -H2126 (adenocarcinomas) and the SCLC lines NCI-H69, -H82, -H841, -H146, -H187, -H526, -H1092, -H510, -24H, 86M1, DMS79 and SW210. The origin and characteristics of these cell lines have been described previously (Wimmel et al., 1997) . All cells were grown in RPMI 1640 medium (GIBCO ± BRL) supplemented with 10% heat-inactivated fetal calf serum (GIBCO ± BRL), nonessential amino acids and 4 mmol/L glutamine. Normal bronchial epithelial (NHBE) cells were obtained from Clonetics Corp. and grown in BEGM medium according to the supplier's instructions.
Whenever necessary, PMA (phorbol 12-myristate 13 acetate, Sigma, dissolved in DMSO) was added to a ®nal concentration of 5610 78 M for the indicated period of time.
Antibodies
Antibodies indicated by an asterisk (see Figure 5) were peptide-speci®c, anity-puri®ed mouse antibodies and were obtained from Santa Cruz Biotechnology, Inc. (a cJun*/sc-45, a JunD*/sc-74, a JunB*/sc-46, a Fra-1*/sc-183, a Fra-2*/sc-171). All other antibodies used were generated and anity-puri®ed as described before (Adamkiewicz et al., 1990; . These comprised the following antisera: a 
Double stranded oligonucleotides
TRE (TPA responsive element=AP-1 consensus sequence Angel, et al. 1987) : 5'-AAGCATGAGTCAGACAC-3' (sense) and corresponding antisense strand, mut. TRE (mutant TRE; Risse et al., 1989) 5'-AAGCACGAGGCA-GACAC-3' (sense) and coresponding antisense strand, Rd (random sequence): 5'-GCGACTAACATCGATCG-3' (sense) and corresponding antisense strand, SP-1 (kindly provided by Dr G Suske, IMT, Marburg): 5'-AGCTTCC-GTTGGGGCGGGGCTTCACG-3' (sense) and 5'-TCGA-CGTGAAGCCCCGCCCCAACGGA-3' (antisense strand). All oligonucleotides were labeled and applied in electrophoretic mobility assays as described earlier (Risse et al., 1989) .
Electrophoretic mobility shift assay (EMSA)
Whole cell extracts were prepared according to a protocol described in Scho È ler et al. (1989) . Binding reactions were performed by incubating 5 or 10 mg of whole cell extract with 0.5 or 1 mg of polydI-dC (Pharmacia Inc.) in a buer containing 10 mM HEPES, pH 7.9, 60 mM KCl, 4% Ficoll, 1 mM EDTA and 1 mM DTT for 30 min at room temperature (Barberis et al., 1987) . One to two femtomoles (5 ± 10610 3 c.p.m.) of 32 P-labeled doublestranded oligonucleotide was then added and incubation was continued for 30 min at room temperature. Protein-DNA complexes were resolved on 4% native polyacrylamide gels in 0.256TBE buer and visualised by autoradiography.
Competition assays were performed by adding the indicated amounts of unlabeled speci®c or random oligonucleotides to the binding reaction 30 min before the addition of 32 P-labeled probe. For speci®c antibody binding, whole cell extracts were preincubated with the respective antisera (10 mg in case of anity-puri®ed antibody, 50 mg in case of antiserum) for 45 min at 48C followed by the addition of the labeled oligonucleotide.
Reverse transcriptase-polymerase chain reaction (RT ± PCR)
Total RNA was prepared from all cell lines using RNAzol B (CINNA/BIOTECX Laboratories INC.) as ready-to-use solution or RNeasy RNA extraction kit (Qiagen) according to the suppliers' protocols. 1 mg RNA was then reverse transcribed using Oligo (d)T as primer and aliquots of the resulting cDNA were used for RT ± PCR. The cDNA was ampli®ed by subsequent PCR for 20 ± 30 cycles (948C for 1 min, 608C for 1 min and 728C for 1 min) in the presence of a-[ 33 P]dCTP. For ampli®cation of c-jun fragments, 5% DMSO was added to the reaction mix. The number of cycles was kept limited in order to ensure a linear ampli®cation of PCR products. The following primers were used for PCR ampli®cation:
GAPDH (Arcari et al., 1984) : 5'primer, 5'-CGTCTTCACCACCATGGAGA 3'primer; 5'-CGGCCATCACGCCACAGTTT CD44 (transmembrane region; Screaton et al., 1992) 5'primer, 5'-GAGACCAAGACACATTCCACC 3'primer, 5'-GCCAAGAGGGATGCCAAGATGA c-fos (Van Straaten et al., 1983) : 5'primer, 5'-ACGCAGA-CTACGAGGCGTCA 3'primer, 5'-TTCACAACGCCAGC-CCTGGA fosB (Siderovski et al., 1990) : 5'primer, 5'-AAAAGCAGAGCTGGAGTCGG 3'primer, 5'-GTACGAAGGGTTAACAACGG fra-1 : 5'primer, 5'-CCAAGCATCAACACCATGAG 3'primer, 5'-AGGGAGATACAAGGTACAGG fra-2 : 5'primer, 5'AAGATTAG-CCCCGAGGAGCG 3'primer, 5'-CAGCAATGCTGATG-GGCTTG c-jun (Hattori et al., 1988) : 5'primer, 5'-TTCACCTT-CTCTCTAACTGC 3'primer, 5' TCACTCACTGAGCGCT-CTTC junD : 5'primer, 5'-TTGTCGC-CCATCGACATGGACA 3'primer, 5'-AGCTCCGTGTTCTGACTCTTGA junB : 5'primer, 5'-CCAGTCCTTCCACCTCGACGTTTACAA 3'primer, 5'-GACTAAGTGC-GTGTTTCTTTTCCACAG.
Aliquots of the PCR reaction were electrophoresed in 6% polyacrylamide for 2 h at room temperature, the gels were dried thereafter and exposed to X-ray ®lm (Kodak X-OMAT AR) for 12 ± 72h.
Immunostaining
N592 and H-ras/c-myc transfected N592.5 cells were grown as xenografts in nu/nu mice for 21 days. Indirect immuno¯uorescence was performed on 4 mm sections of the resulting tumors with murine monoclonal antibody against the CD44 standard form (clone SFF-2, Bender MedSystems) and alkaline phosphatase conjugated rabbit a-mouse second antibody. Enzymatic conversion of uorescent substrate followed a protocol provided by the manufacturer (Molecular Probes, Leiden, The Netherlands) and antibody binding was then visualised by¯uorescence microscopy. Counterstaining was performed with Hoechst 33258.
